Stock Selection: Muse Spark 1.1's picks for 2026-10-12
Muse Spark 1.1 picked CRM, FSLR, AMZN, MSFT, TSLA for a 1-day horizon. Portfolio return vs SPY: +0.72%. Picks that beat SPY: 60%.
| Experiment | Stock Selection |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-12 |
| Measured to | 2026-10-13 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +0.72% |
| Picks that beat SPY | 60% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | CRM | +3.27% | 75% | +3.33% | Yes |
| 2 | FSLR | -0.71% | 71% | -0.65% | No |
| 3 | AMZN | +0.25% | 68% | +0.31% | Yes |
| 4 | MSFT | +1.88% | 65% | +1.94% | Yes |
| 5 | TSLA | -1.35% | 62% | -1.29% | No |
The model's market view
SPY closed Oct 10 near 778.57 up 0.60% Friday, futures indicated cautious positive open Oct 12 on sticky inflation expectations. Mag7 split with AMZN/MSFT/TSLA leading premarket up 2-3% while AAPL/NVDA/META lagging. News-driven upgrades in software (【entity-Salesforce¦canonical_name=Salesforce】) and solar (First Solar) creating idiosyncratic momentum likely to outperform broad index over 1 session. Equal-weight beta names with positive premarket triggers favored for short-term relative strength.
Why each pick
CRM
【entity-Salesforce¦canonical_name=Salesforce】 up 4% premarket on BofA upgrade to Buy from Underperform, thesis that AI deepens dependence rather than disrupts. Previous close 229.13, current quote 235.51 showing continuation. Strongest idiosyncratic catalyst among large-cap software today. Risks: upgrade already priced in premarket gap, enterprise software beta to rates, broad market pullback on inflation expectations could erase gap.
FSLR
First Solar gained 2.4% premarket after Truist raised to Buy from Hold citing solar demand growth and pricing power. Finnhub current 184.37 vs previous close 177.82 (+3.68%). Solar sector momentum plus analyst catalyst gives high beta to outperform SPY in 1d. Risks: solar volatility (beta 1.74), policy risk, prior 1-month -11.8% downtrend may see profit-taking.
AMZN
Top Mag7 premarket mover +3.29% to 262.43 as of Oct 12 07:16 snapshot. Intraday high 263.70 showing momentum continuation. No negative news, price above trigger levels noted in dark pool report targeting 265-275. High liquidity large-cap likely to carry momentum into regular session. Risks: Cantor Fitzgerald cut target to 310 from 320, overweight remains, but valuation concern and broad market cautious on inflation could limit follow-through.
MSFT
Microsoft premarket bullish +2.38% to 535.07, current 538.51 (+0.64% intraday). Deutsche Bank reaffirmed Buy raising target to 600 from 550, implying 11% upside. Strong 5-day +4.05% and 6-month +45.2% trend, defensive AI infrastructure play. Risks: trading near 52-week high 554, elevated P/E ~29x, Phillip Securities downgrade to Neutral, potential mean reversion vs SPY.
TSLA
Tesla premarket bullish +2.05% to 382.70, current 379.65 after overnight climb on Cybercab Dallas expansion and Musk chip fab commentary. Short-term 7-day +3.27% momentum, holding above moving average stack per technical coverage. High beta name (1.76) that amplifies SPY upside in risk-on session. Risks: elevated valuation P/E 397x, volatile on Musk headlines, previous close already captured 2.05% gain so intraday follow-through needed to beat SPY.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| GPT-6 | FSLR, CRM, CCC, CVX, IREN | -0.42% | 60% |
| Gemini 3 Pro | NVDA, MSFT, QQQ, AAPL, AMZN | +0.71% | 80% |
| Perplexity | CCI, MRNA, HUM, NVAX, FSLY | -0.84% | 40% |
| Grok 4.5 | XLE, XOM, CRM, DHT, JPM | +1.16% | 80% |
| Claude Sonnet 5.5 | XOM, JPM, NVDA, CVX, XLU | +0.28% | 60% |
| DeepSeek | IREN, CCC, CRM, BIIB, FSLR | -1.00% | 40% |
Written up on ForecastNest Insights: Stock Selection: Muse Spark 1.1's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.